Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the <scp><i>BRAF</i> V600E</scp> mutation
Yosuke Dotsu(Nagasaki University), Hiroshi Mukae(Nagasaki University), Hiroshi Gyotoku, Yasushi Obase(Nagasaki University Hospital), Shinnosuke Takemoto(Nagasaki University), Noriho Sakamoto(Nagasaki University), Kazuto Ashizawa(Nagasaki University), Hirokazu Taniguchi(Memorial Sloan Kettering Cancer Center), Hiroaki Ikeda(Nagasaki University), Takayuki Suyama(Sasebo City General Hospital), Hiroyuki Yamaguchi(Funabashi Municipal Medical Center), Yasuhiro Umeyama(Nagasaki University), Minoru Fukuda(Nagasaki Prefectural Shimabara High School), Yoshihisa Kohno(Nagasaki Ajisai Hospital), Taiga Miyazaki(University of Miyazaki Hospital), Noritaka Honda(Nagasaki University)
Cited by 5
Related Papers
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM
|Lara D. Veeken|2012|321
Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study
|Journal of Thoracic Oncology|2016|273
Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
|Clinical Cancer Research|2015|180